ArticleBMC neurology2014
Corticosteroid therapy in regressive autism: a retrospective study of effects on the Frequency Modulated Auditory Evoked Response (FMAER), language, and behavior.
Article in BMC neurology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 47 citations in OpenAlex.
- Systematic review and meta-analysis: multimodal functional and anatomical neural alterations in autism spectrum disorder.Molecular autism · 2024Pooled it
- Effect of prednisolone on language function in children with autistic spectrum disorder: a randomized clinical trial.Jornal de pediatriaTrial
- Relationship Between Calcium and Gut Microbial Composition and Metabolic Pathways in Children with Autism.Metabolites · 2026Article
- Medical treatment of autism spectrum disorder in children: Current evidence, controversies, and clinical challenges.World journal of clinical pediatrics · 2026Article
- Electroencephalography in Autism Spectrum Disorder.Journal of clinical medicine · 2025Review
- Gut microbial 'TNFα-sphingolipids-steroid hormones' axis in children with autism spectrum disorder: an insight from meta-omics analysis.Journal of translational medicine · 2024Article
- Pharmacotherapy for the core symptoms of autism spectrum disorder.Journal of Zhejiang University. Science. B · 2024Review
- Peripheral Inflammatory Markers in Autism Spectrum Disorder and Attention Deficit/Hyperactivity Disorder at Adolescent Age.International journal of molecular sciences · 2023Article
- Review
- Differences of gut microbiota and behavioral symptoms between two subgroups of autistic children based on γδT cells-derived IFN-γ Levels: A preliminary study.Frontiers in immunology · 2023Article
- Autoimmune Encephalitis and Autism Spectrum Disorder.Frontiers in psychiatry · 2021Review
- Electroencephalographic Abnormalities in Autism Spectrum Disorder: Characteristics and Therapeutic Implications.Medicina (Kaunas, Lithuania) · 2020Review
- Combination of Steroid and Flavonoid for the Treatment of Regressive Autism.Journal of neurosciences in rural practice · 2020Article
- Immune regulation of neurodevelopment at the mother-foetus interface: the case of autism.Clinical & translational immunology · 2020Review
- Beyond the brain: A multi-system inflammatory subtype of autism spectrum disorder.Psychopharmacology · 2019Review
- Review of Clinical Studies Targeting Inflammatory Pathways for Individuals With Autism.Frontiers in psychiatry · 2019Review
- Is Autism Inborn And Lifelong For Everyone?Neuropsychiatric disease and treatment · 2019Article
- Immune Abnormalities in Autism Spectrum Disorder-Could They Hold Promise for Causative Treatment?Molecular neurobiology · 2018Review
- Inflammation and Neuro-Immune Dysregulations in Autism Spectrum Disorders.Pharmaceuticals (Basel, Switzerland) · 2018Review
- Immune Dysfunction and Autoimmunity as Pathological Mechanisms in Autism Spectrum Disorders.Frontiers in cellular neuroscience · 2018Review
Corrections and comments
- Commented on by
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundUp to a third of children with Autism Spectrum Disorder (ASD) manifest regressive autism (R-ASD).They show normal early development followed by loss of language and social skills. Absent evidence-based therapies, anecdotal evidence suggests improvement following use of corticosteroids. This study examined the effects of corticosteroids for R-ASD children upon the 4 Hz frequency modulated evoked response (FMAER) arising from language cortex of the superior temporal gyrus (STG) and upon EEG background activity, language, and behavior. An untreated clinical convenience sample of ASD children served as control sample.
methodsTwenty steroid-treated R-ASD (STAR) and 24 not-treated ASD patients (NSA), aged 3 - 5 years, were retrospectively identified from a large database. All study participants had two sequential FMAER and EEG studies;Landau-Kleffner syndrome diagnosis was excluded. All subjects' records contained clinical receptive and expressive language ratings based upon a priori developed metrics. The STAR group additionally was scored behaviorally regarding symptom severity as based on the Diagnostic and Statistical Manual IV (DSM-IV) ASD criteria list. EEGs were visually scored for abnormalities. FMAER responses were assessed quantitatively by spectral analysis. Treated and untreated group means and standard deviations for the FMAER, EEG, language, and behavior, were compared by paired t-test and Fisher's exact tests.
resultsThe STAR group showed a significant increase in the 4 Hz FMAER spectral response and a significant reduction in response distortion compared to the NSA group. Star group subjects' language ratings were significantly improved and more STAR than NSA group subjects showed significant language improvement. Most STAR group children showed significant behavioral improvement after treatment. STAR group language and behavior improvement was retained one year after treatment. Groups did not differ in terms of minor EEG abnormalities. Steroid treatment produced no lasting morbidity.
conclusionsSteroid treatment was associated with a significantly increased FMAER response magnitude, reduction of FMAER response distortion, and improvement in language and behavior scores. This was not observed in the non-treated group. These pilot findings warrant a prospective randomized validation trial of steroid treatment for R-ASD utilizing FMAER, EEG, and standardized ASD, language and behavior measures, and a longer follow-up period.Please see related article http://www.biomedcentral.com/1741-7015/12/79.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.